Aileron Therapeutics (NASDAQ:ALRN) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Aileron Therapeutics (NASDAQ:ALRN) posted its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05), Fidelity Earnings reports.

ALRN stock traded up $0.04 during midday trading on Friday, hitting $0.56. 313,300 shares of the company’s stock were exchanged, compared to its average volume of 336,292. The stock’s fifty day moving average price is $0.55 and its 200-day moving average price is $0.82. The company has a market cap of $15.69 million, a PE ratio of -0.27 and a beta of 2.21. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.04 and a current ratio of 6.04. Aileron Therapeutics has a one year low of $0.40 and a one year high of $2.60.

ALRN has been the topic of several recent research reports. Zacks Investment Research lowered Aileron Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. ValuEngine upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Aileron Therapeutics in a research report on Monday, September 30th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Aileron Therapeutics presently has a consensus rating of “Buy” and an average price target of $4.00.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

In other news, SVP Vojo Vukovic bought 75,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were bought at an average price of $0.59 per share, with a total value of $44,250.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Kathryn Gregory bought 45,000 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was purchased at an average cost of $0.65 per share, for a total transaction of $29,250.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 265,211 shares of company stock worth $207,650. Company insiders own 6.20% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Featured Article: Convertible Shares

Earnings History for Aileron Therapeutics (NASDAQ:ALRN)

Leave a Reply

Your email address will not be published. Required fields are marked *